吉非替尼对比长春瑞滨联合顺铂辅助治疗II-IIIA期EGFR突变NSCLC的III期随机研究
ADJUVANT/CTONG1104研究为随机、开放标签、III期试验,纳入222例完全切除的II-IIIA期(N1-N2)EGFR突变NSCLC患者,比较吉非替尼(250mg每日一次,24个月)与长春瑞滨联合顺铂辅助治疗的疗效。吉非替尼组3级及以上不良事件及严重不良事件较少,但24个月后获益可能有限,总生存数据尚未成熟。
要点
- 吉非替尼辅助治疗显著延长II-IIIA期EGFR突变NSCLC患者无病生存期。
- 吉非替尼组严重不良事件发生率低于长春瑞滨联合顺铂组。
- 总生存数据尚未成熟,吉非替尼24个月后获益可能有限。
核心结论
- 对于完全切除的II-IIIA期(N1-N2)EGFR突变NSCLC患者,辅助吉非替尼较长春瑞滨联合顺铂显著延长无病生存期。
研究设计与样本
- 随机、开放标签、III期试验,在中国27个中心开展,纳入222例完全切除(R0)的II-IIIA期(N1-N2)EGFR突变(19外显子缺失或21外显子L858R)NSCLC患者,按1:1随机分配至吉非替尼组(111例)或长春瑞滨联合顺铂组(111例)。
主要发现
- 安全性人群中,吉非替尼组(n=106)最常见的3级及以上不良事件为丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高(各2例[2%]),长春瑞滨联合顺铂组(n=87)为中性粒细胞减少(30例[34%])、白细胞减少(14例[16%])和呕吐(8例[9%])。
- 吉非替尼组严重不良事件报告7例(7%),长春瑞滨联合顺铂组20例(23%);吉非替尼组未观察到间质性肺病,无治疗相关死亡。
临床怎么用
- 对于完全切除的II-IIIA期(N1-N2)EGFR突变NSCLC患者,辅助吉非替尼可作为辅助化疗的潜在替代选择。
局限性
- 吉非替尼24个月后的获益持续时间可能有限,总生存数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II-IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB-IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA (N1-N2) NSCLC. METHODS: We did a randomised, open-label, phase 3 trial at 27 centres in China. We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC. Patients were stratified by N stage and EGFR mutation status and randomised (1:1) by Pocock and Simon minimisation with a random element to either gefitinib (250 mg once daily) for 24 months or intravenous vinorelbine (25 mg/m2 on days 1 and 8) plus intravenous cisplatin (75 mg/m2 on day 1) every 3 weeks for four cycles. The primary endpoint was disease-free survival in the intention-to-treat population, which comprised all randomised patients; the safety population included all randomised patients who received at least one dose of study medication. Enrolment to the study is closed but survival follow-up is ongoing. The study is registered with ClinicalTrials.gov, number NCT01405079. FINDINGS: Between Sept 19, 2011, and April 24, 2014, 483 patients were screened and 222 patients were randomised, 111 to gefitinib and 111 to vinorelbine plus cisplatin. Median follow-up was 36·5 months (IQR 23·8-44·8). Median disease-free survival was significantly longer with gefitinib (28·7 months [95% CI 24·9-32·5]) than with vinorelbine plus cisplatin (18·0 months [13·6-22·3]; hazard ratio [HR] 0·60, 95% CI 0·42-0·87; p=0·0054). In the safety population, the most commonly reported grade 3 or worse adverse events in the gefitinib group (n=106) were raised alanine aminotransferase and asparate aminotransferase (two [2%] patients with each event vs none with vinorelbine plus cisplatin). In the vinorelbine plus cisplatin group (n=87), the most frequently reported grade 3 or worse adverse events were neutropenia (30 [34%] patients vs none with gefitinib), leucopenia (14 [16%] vs none), and vomiting (eight [9%] vs none). Serious adverse events were reported for seven (7%) patients who received gefitinib and 20 (23%) patients who received vinorelbine plus cisplatin. No interstitial lung disease was noted with gefitinib. No deaths were treatment related. INTERPRETATION: Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC. Based on the superior disease-free survival, reduced toxicity, and improved quality of life, adjuvant gefitinib could be a potential treatment option compared with adjuvant chemotherapy in these patients. However, the duration of benefit with gefitinib after 24 months might be limited and overall survival data are not yet mature. FUNDING: Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine; National Health and Family Planning Commission of People's Republic of China; Guangzhou Science and Technology Bureau; AstraZeneca China.
引用
- Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2017. PMID: 29174310. doi:10.1016/S1470-2045(17)30729-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。